Ferric Carboxymaltose

Request Quote

Molecular Formula – 

Molecular Weight – 

CAS No – 

Shelf Life – 

HSN Code –  

Packing Size – 

Storage Condition – 

Additional Info – 

Single Dose of Intravenous Ferric Carboxymaltose Prevents Anemia for 6 Months among Moderately or Severely Anemic Postpartum Women: A Case Study from India

ABSTRACT The effectiveness of intravenous ferric carboxymaltose (FCM) in quickly increasing normal hemoglobin concentration and replenishing body iron reserves up to 6–12 wk is known; however, its long-term effectiveness is unknown. In this study conducted in northern India during August...

Read more
Effects of ferric carboxymaltose on hemoglobin level after cardiac surgery: A randomized controlled trial

Abstract Background Perioperative anemia is common in cardiac surgery. Few studies investigated the effect of postoperative intravenous (IV) iron supplementation and were mostly inconclusive. Methods Design: A randomized single-center, double-blind, placebo-controlled, parallel-group trial. Participants: 195 non-anemic patients were recruited from...

Read more
Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial

Author links open overlay panel Nanja Bevers MD 1, Els Van de Vijver PhD, MD 2, Arta Aliu 1, Ashkan Rezazadeh Ardabili MD 3, Philippe Rosias MD, PhD 1, Janneke Stapelbroek MD, PhD 4, Imke A. Bertrams Maartens MD 5,...

Read more
Abstract 13788: Intravenous Iron Replacement Therapy With Ferric Carboxymaltose is Safe and Effective in Pediatric Patients With Heart Failure

Abstract Introduction: Iron deficiency (ID) is associated with worse outcomes in patients with heart failure (HF). In adults with HF and ID, intravenous (IV) iron replacement therapy (IRT) improves HF outcomes and is the first-line therapy for ID because oral...

Read more
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency

Background: Iron deficiency is common in patients with heart failure (HF) and is associated with reduced exercise capacity and poor outcomes. Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak oxygen consumption [peak VO2], an objective measure...

Read more
Abstract 12081: Beneficial Effects of Ferric Carboxymaltose in Patients With Pulmonary Arterial Hypertension and Iron Deficiency: A Long-term Study

Introduction: PAH is a progressive disease with limited prognosis. Iron deficiency (ID) correlates in PAH patients with disease severity and mortality. Oral iron resorption is impaired by hepcidine in PAH. In a former pilot study, we could demonstrate a short-term...

Read more
Download Brochure
Contact Us